Your search returned 5 results. Subscribe to this search

Not what you expected? Check for suggestions
|
1. Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?

by Joshi A | Noronha V | Patil VM | Chougule A | Bhattacharjee A | Kumar R | Goud S | More S | Ramaswamy A | Karpe A | Pande N | Chandrasekharan A | Goel A | Talreja V | Mahajan A | Janu A | Purandare N | Prabhash K.

In Chemotherapy Research and Practice
Material type: article Article; Format: print Publisher: 2017Availability: Items available for loan: Tata Memorial Hospital (1).

2. P3.02b-055 Impact of pemetrexed chemotherapy in exon 19 or exon 21 mutated nsclc

by Talreja V | Noronha V | Patil V | Joshi A | Chougule A | Mahajan A | Janu A | Goud S | More S | Karpe A | Ramaswamy A | Pande N | Chandrasekharan A | Goel A | Prabhash K.

In Journal of Thoracic Oncology
Material type: article Article; Format: print Publisher: New York, NY : Elsevier 2017Online access: PDF Availability: Items available for loan: Tata Memorial Hospital (1).

3. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma

by Patil VM | Noronha V | Joshi A | Choughule AB | Bhattacharjee A | Kumar R | Goud S | More S | Ramaswamy A | Karpe A | Pande N | Chandrasekharan A | Goel A | Talreja V | Mahajan A | Janu A | Purandare N | Prabhash K [Corresponding author].

In ESMO Open
Material type: article Article; Format: print Publisher: 2017Availability: Items available for loan: Tata Memorial Hospital (1).

4. Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of a Phase III randomized trial to compare the benefit of gefitinib versus pemetrexed/ carboplatin for epidermal growth factor receptor-mutated non-small cell lung cancer

by Patil V | Noronha V | Joshi A | Chougule A | Bhattacharjee A | Goel A | Talreja V | Menon N | Ramaswamy A | Karpe A | Pande N | Chandrasekharan A | Mahajan A | Janu A | Purandare N | Kumar P [Corresponding Author].

In Cancer Research, Statistics, and Treatment
Material type: article Article; Format: print Publisher: 2019Availability: Items available for loan: Tata Memorial Hospital (1).

5. Tyrosine kinase inhibitor versus physician choice chemotherapy in second-line epidermal growth factor receptor mutation non-small cell lung cancer: Post hoc analysis of randomized control trial

by Noronha V | Pandey A | Patil V | Joshi A | Choughule AB | Bhattacharjee A | Kumar R | Goud S | More S | Ramaswamy A | Karpe A | Pande N | Chandrasekharan A | Goel A | Talreja V | Mahajan A | Janu A | Purandare N | Prabhash K [Corresponding author].

In Indian Journal of Medical and Paediatric Oncology
Material type: article Article; Format: print Publisher: 2018Availability: Items available for loan: Tata Memorial Hospital (1).

Powered by Koha